Summit Therapeutics Statistics
Share Statistics
Summit Therapeutics has 737.09M shares outstanding. The number of shares has increased by 3.35% in one year.
| Shares Outstanding | 737.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 103.50M |
| Failed to Deliver (FTD) Shares | 248 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 17.04M, so 2.31% of the outstanding shares have been sold short.
| Short Interest | 17.04M |
| Short % of Shares Out | 2.31% |
| Short % of Float | 16.46% |
| Short Ratio (days to cover) | 5.67 |
Valuation Ratios
The PE ratio is -2.63 and the forward PE ratio is -55.66.
| PE Ratio | -2.63 |
| Forward PE | -55.66 |
| PS Ratio | 0 |
| Forward PS | 391.3 |
| PB Ratio | 20.82 |
| P/FCF Ratio | -21.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Summit Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.3, with a Debt / Equity ratio of 1.29.
| Current Ratio | 9.3 |
| Quick Ratio | 9.3 |
| Debt / Equity | 1.29 |
| Total Debt / Capitalization | 56.28 |
| Cash Flow / Debt | -0.77 |
| Interest Coverage | -5.45 |
Financial Efficiency
Return on equity (ROE) is -7.91% and return on capital (ROIC) is -48.75%.
| Return on Equity (ROE) | -7.91% |
| Return on Assets (ROA) | -3.03% |
| Return on Capital (ROIC) | -48.75% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -5.86M |
| Employee Count | 105 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -946.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 598.83% in the last 52 weeks. The beta is -0.92, so Summit Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.92 |
| 52-Week Price Change | 598.83% |
| 50-Day Moving Average | 19.64 |
| 200-Day Moving Average | 11.73 |
| Relative Strength Index (RSI) | 43.47 |
| Average Volume (20 Days) | 3.36M |
Income Statement
In the last 12 months, Summit Therapeutics had revenue of $0 and earned -$614.93M in profits. Earnings per share was $-0.99.
| Revenue | 0 |
| Gross Profit | -2.05M |
| Operating Income | -89.74M |
| Net Income | -614.93M |
| EBITDA | 1.00M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.99 |
Balance Sheet
The company has $71.42M in cash and $106.10M in debt, giving a net cash position of -$34.67M.
| Cash & Cash Equivalents | 71.42M |
| Total Debt | 106.10M |
| Net Cash | -34.67M |
| Retained Earnings | -993.26M |
| Total Assets | 502.85M |
| Working Capital | 431.28M |
Cash Flow
In the last 12 months, operating cash flow was -$76.76M and capital expenditures -$128.00K, giving a free cash flow of -$76.89M.
| Operating Cash Flow | -76.76M |
| Capital Expenditures | -128.00K |
| Free Cash Flow | -76.89M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.53% |
| FCF Yield | -0.58% |
Analyst Forecast
The average price target for SMMT is $31.5, which is 76.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.5 |
| Price Target Difference | 76.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 118.31 |
| Piotroski F-Score | 2 |